



**Therapies for major infectious
diseases and related cancers**

Julie Phillips, CEO

www.biodiem.com

jphillips@biodiem.com

(ASX:BDM)


BioDiem Limited



As at 25 September 2012	
Market Cap	\$6.33m
52 week range	5.4 – 10.0¢
Cash	\$1.37m
Shares	102,095,554
Shareholders	919
Revenue FY2012	\$1.3m

Company Focus

- Flu vaccine technology licensed, generating revenues
- Vaccine technologies and infectious disease therapies in development
- Multiple products focused on high value cancer and infectious disease targets
- Cost-effective development with international partnering network (incl. USAMRIID, WHO, NIH, VIVALIS, Serum Institute of India, Australian Universities)



A compelling investment case



Extensive technology portfolio targeting multiple infectious diseases and cancers, supported by:

- Existing flu vaccine technology license income provides revenue base
- Existing licenses to WHO, Serum Institute of India & BCHT, China (2012)
- Superior vaccine product licensed to WHO as part of Global Pandemic Influenza Action Plan
- Post-marketing trials are close to completion and are expected to facilitate international exports
- 2011/12 licensing revenue of A\$1.3 million

A strong pipeline of products with high value disease targets, including:

- **Large markets:** influenza, schistosomiasis, hepatitis, TB
- **High-value niche markets:** fungal diseases, MRSA, sexually transmitted diseases, viral-related cancers
- **Influenza vaccine** already on the market

Extensive global partnership network with leading research institutions and companies

- Partnering strategy accelerates development, lowers cost, while retaining IP control

Multiple proprietary vaccine platform technologies for licensing

- Targeting multiple infectious diseases and related cancers
- Co-development strategy with commercial partners (e.g. VIVALIS on the LAIV vector platform)
- Licensing model targets other vaccine developers to create new vaccines and royalty income

LAIV Vector platform: A viral vector can deliver a customised protein into the body to produce a Protective or Boosted immune response to fight a disease e.g. nasopharyngeal cancer or respiratory syncytial virus infection.

First stage of commercial platform project completed with VIVALIS.

Hepatitis D vaccine platform: a proprietary method using of hepatitis D virus to target hepatitis D and hepatitis B.

SAVINE platform: The “scrambled antigen vaccine” technology allows design of customised proteins e.g. NPC SAVINE for Epstein Barr virus-related diseases; TB SAVINE for tuberculosis.

Flavivirus technology platform: targeting dengue fever, Murray River encephalitis and Japanese encephalitis, and others.

One in six cancers is linked to a virus infection
Platform technology → multiple new vaccine possibilities for cancers and infectious diseases

Exciting broad-spectrum antimicrobial



- **Increasing resistance** to antibiotics is a major concern for healthcare systems worldwide.
- BioDiem’s BDM-I antimicrobial has demonstrated activity in US screening studies against a **wide range** of disease-causing bacteria, fungi, protozoa and parasites in a significant number of screening studies.
- BDM-I is currently being researched as treatment against ‘superbugs’ or antibiotic-resistant bacteria such as MRSA, and the serious fungal infection, aspergillosis.
- Big Pharma are focusing on this space, and looking to acquire. Product pipelines are running dry so innovative products are in high demand

Product	Disease Targets	Current Partners	Development Status
BDM-I (Antimicrobial)	Bacterial infections (MRSA, tuberculosis)	US government backed research institutions	Success in activity screening program, patents granted for major indications
	Fungal infections (Aspergillus, Scedosporium, yeasts and others)	US government backed research institutions University of Sydney	Positive screening results in difficult to treat fungi, patents granted for major indications
	Parasitic diseases (schistosomiasis, others)	QIMR program	Success in activity screening program, patents granted for major indications



Why BioDiem?

- BioDiem has **successfully licensed its flu vaccine** to the largest markets in the world: a **proven track record** of new license growth
- **Global partnering strategy** with research leaders accelerates development and delivers more for each \$R&D.
- Potential to engineer **multiple new vaccines** from vector platform.
- **Exciting potential for antimicrobial program** across multiple acute and chronic infectious diseases with opportunities for accelerated regulatory approval.

Near-term value drivers

Next six months:

1. **Additional licence revenues** from existing influenza vaccine technology
2. **Phase I clinical trial results** for avian flu vaccine (results to support stockpiling for future pandemic)
3. **Next stage of vector program** to demonstrate new viruses carrying antigens customised to fight specific diseases.
4. **Results** from expanded BDM-I bacterial/fungal/parasite **screening studies**
5. **Hepatitis vaccine progress** including potential grants/partnering.

Next twelve months:

1. **Expand sales** and use of LAIV in **new territories**
2. **New cell-based LAIV license** negotiations
3. **Results** from **BDM-I testing in animal models** for target microbial and fungal diseases.
4. **Completion of BDM-E out-licensing or sale**